David Malek Buys 4,166 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Malek acquired 4,166 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $74,988.00. Following the completion of the acquisition, the director directly owned 533,845 shares in the company, valued at $9,609,210. This represents a 0.79% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Braveheart Bio Price Performance

NASDAQ:BRVE traded up $0.20 during mid-day trading on Friday, reaching $30.00. The company’s stock had a trading volume of 566,417 shares. Braveheart Bio, Inc. has a 12-month low of $28.47 and a 12-month high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.